Suppression of Cytosolic NADPH Pool by Thionicotinamide Increases Oxidative Stress and Synergizes with Chemotherapy

Molecular Pharmacology

Volumn 88, Issue 4, 2015, Pages 720-727

  Tedeschi, Philip M ^a   Lin, Hong Xia ^a   Gounder, Murugesan ^a   Kerrigan, John E ^a   Abali, Emine Ercikan ^b   Scotto, Kathleen ^a   Bertino, Joseph R ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; GEMCITABINE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; IRINOTECAN; PHOSPHOTRANSFERASE INHIBITOR; PRODRUG; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SHORT HAIRPIN RNA; THIONICOTINAMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; VALIDATION STUDY; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CYTOSOL; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; METABOLISM; NONOBESE DIABETIC MOUSE; PHYSIOLOGY; PROCEDURES; SCID MOUSE; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOSOL; DRUG SYNERGISM; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NADP; NIACINAMIDE; OXIDATIVE STRESS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84947920445     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.096727     Document Type: Article

References (37)

1. Beck R, Pedrosa RC, Dejeans N, Glorieux C, Levêque P, Gallez B, Taper H, Eeckhoudt S, Knoops L, and Calderon PB et al. (2011) Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study. Invest New Drugs 29:891-900.
2. Cairns RA, Harris IS, and Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11:85-95.
3. Chiarugi A, Dölle C, Felici R, and Ziegler M (2012) The NAD metabolome-a key determinant of cancer cell biology. Nat Rev Cancer 12:741-752.
4. Chintala S, Tóth K, Yin M-B, Bhattacharya A, Smith SB, Ola MS, Cao S, Durrani FA, Zinia TR, and Dean R et al. (2010) Downregulation of cystine transporter xc by irinotecan in human head and neck cancer FaDu xenografts. Chemotherapy 56: 223-233.
5. Chou TC and Talalay P (1984) Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
6. Dietrich LS, Friedland IM, and Kaplan LA (1958) Pyridine nucleotide metabolism: mechanism of action of the niacin antagonist, 6-aminonicotinamide. J Biol Chem 233:964-968.
7. El Sayed SM, Mahmoud AA, El Sawy SA, Abdelaal EA, Fouad AM, Yousif RS, Hashim MS, Hemdan SB, Kadry ZM, and Abdelmoaty MA et al. (2013) Warburg effect increases steady-state ROS condition in cancer cells through decreasing their antioxidant capacities (anticancer effects of 3-bromopyruvate through antagonizing Warburg effect). Med Hypotheses 81:866-870.
8. Estrela JM, Ortega A, and Obrador E (2006) Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 43:143-181.
9. Herter FP, Weissman SG, Thompson HG Jr, Hyman G, and Martin DS (1961) Clinical experience with 6-aminonicotinamide. Cancer Res 21:31-37.
10. Hsieh Y-C, Tedeschi P, Adebisi Lawal R, Banerjee D, Scotto K, Kerrigan JE, Lee K-C, Johnson-Farley N, Bertino JR, and Abali EE (2013) Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs. Mol Pharmacol 83:339-353.
11. Icard P and Lincet H (2012) A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells. Biochim Biophys Acta 1826: 423-433.
12. Kim SU and Wenger BS (1973) Neurotoxic effects of 6-aminonicotinamide on cultures of central nervous tissue. Acta Neuropathol 26:259-264.
13. Kirsch M, Talbiersky P, Polkowska J, Bastkowski F, Schaller T, de Groot H, Klärner F-G, and Schrader T (2009) A mechanism of efficient G6PD inhibition by a molecular clip. Angew Chem Int Ed Engl 48:2886-2890.
14. Köhler E, Barrach H, and Neubert D (1970) Inhibition of NADP dependent oxidoreductases by the 6-aminonicotinamide analogue of NADP. FEBS Lett 6:225-228.
15. Litt MR, Potter JJ, Mezey E, and Mitchell MC (1989) Analysis of pyridine dinucleotides in cultured rat hepatocytes by high-performance liquid chromatography. Anal Biochem 179:34-36.
16. Longo GS, Izzo J, Gorlick R, Banerjee D, Jhanwar SC, and Bertino JR (2001) Characterization and drug sensitivity of four newly established colon adenocarcinoma cell lines to antifolate inhibitors of thymidylate synthase. Oncol Res 12:309-314.
17. Lu J and Holmgren A (2014) The thioredoxin antioxidant system. Free Radic Biol Med 66:75-87.
18. Maehara S, Tanaka S, Shimada M, Shirabe K, Saito Y, Takahashi K, and Maehara Y (2004) Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells. Int J Cancer 112:184-189.
19. Ogasawara Y, Funakoshi M, and Ishii K (2009) Determination of reduced nicotinamide adenine dinucleotide phosphate concentration using high-performance liquid chromatography with fluorescence detection: ratio of the reduced form as a biomarker of oxidative stress. Biol Pharm Bull 32:1819-1823.
20. Ohashi K, Kawai S, and Murata K (2012) Identification and characterization of a human mitochondrial NAD kinase. Nat Commun 3:1248.
21. Pandolfi PP, Sonati F, Rivi R, Mason P, Grosveld F, and Luzzatto L (1995) Targeted disruption of the housekeeping gene encoding glucose 6-phosphate dehydrogenase (G6PD): G6PD is dispensable for pentose synthesis but essential for defense against oxidative stress. EMBO J 14:5209-5215.
22. Patra KC and Hay N (2014) The pentose phosphate pathway and cancer. Trends Biochem Sci 39:347-354.
23. Pelicano H, Carney D, and Huang P (2004) ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 7:97-110.
24. Penkowa M, Camats J, Hadberg H, Quintana A, Rojas S, Giralt M, Molinero A, Campbell IL, and Hidalgo J (2003) Astrocyte-targeted expression of interleukin-6 protects the central nervous system during neuroglial degeneration induced by 6- Aminonicotinamide. J Neurosci Res 73:481-496.
25. Petitprez A, Poindessous V, Ouaret D, Regairaz M, Bastian G, Guérin E, Escargueil AE, and Larsen AK (2013) Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status. Int J Oncol 42: 1644-1653.
26. Petrelli R, Felczak K, and Cappellacci L (2011) NMN/NaMN adenylyltransferase (NMNAT) and NAD kinase (NADK) inhibitors: chemistry and potential therapeutic applications. Curr Med Chem 18:1973-1992.
27. Petrelli R, Sham YY, Chen L, Felczak K, Bennett E, Wilson D, Aldrich C, Yu JS, Cappellacci L, and Franchetti P et al. (2009) Selective inhibition of nicotinamide adenine dinucleotide kinases by dinucleoside disulfide mimics of nicotinamide adenine dinucleotide analogues. Bioorg Med Chem 17:5656-5664.
28. Pollak N, Dölle C, and Ziegler M (2007) The power to reduce: pyridine nucleotides- small molecules with a multitude of functions. Biochem J 402:205-218.
29. Sikkeland J, Jin Y, and Saatcioglu F (2014) Methods to assess lipid accumulation in cancer cells, in Methods in Enzymology (Galluzzi L and Kroemer G, eds) pp 407-423, Academic Press, San Diego, CA.
30. Sinha BK, Mimnaugh EG, Rajagopalan S, and Myers CE (1989) Adriamycin activation and oxygen free radical formation in human breast tumor cells: protective role of glutathione peroxidase in adriamycin resistance. Cancer Res 49:3844-3848.
31. Stein AM, Lee JK, Anderson CD, and Anderson BM (1963) The thionicotinamide analogs of DPN and TPN. I. Preparation and analysis. Biochemistry 2:1015-1017.
32. Teicher BA, Linehan WM, and Helman LJ (2012) Targeting cancer metabolism. Clin Cancer Res 18:5537-5545.
33. Vander Heiden MG (2011) Targeting cancer metabolism: A therapeutic window opens. Nat Rev Drug Discov 10:671-684.
34. Vander Heiden MG, Cantley LC, and Thompson CB (2009) Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324: 1029-1033.
35. Wang X-T and Engel PC (2009) Clinical mutants of human glucose 6-phosphate dehydrogenase: impairment of NADP(1) binding affects both folding and stability. Biochim Biophys Acta 1792:804-809.
36. Ying W (2008) NAD1/NADH and NADP1/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal 10:179-206.
37. Zhang R (2015) MNADK, a long-awaited human mitochondrion-localized NAD kinase. J Cell Physiol 230:1697-1701.